U.S. Stem Cell, Inc.: management transactions · United States · SEC (Form 4)

About U.S. Stem Cell, Inc.

U.S. Stem Cell, Inc. is a U.S.-based healthcare and biotechnology company focused on regenerative medicine and cell therapy. For investors, it is best viewed as a small-cap, high-risk biotechnology story in the United States market; the company has historically been associated with OTC trading rather than a large-cap NYSE or NASDAQ listing, and its corporate footprint has been centered in Sunrise, Florida. Founded in 1999, the company was formerly known as Bioheart, Inc., and later rebranded to U.S. Stem Cell to better reflect its emphasis on stem-cell and cellular-therapy applications. The company’s core business has centered on the discovery, development, and commercialization of autologous and cell-based therapies, especially in cardiovascular and regenerative-medicine use cases. Its flagship historical product candidate, MyoCell, is an autologous muscle stem-cell therapy intended to help improve cardiac function after serious heart damage. Public disclosures also show a broader business mix over time: physician training, cell collection and storage services, treatment kits, and clinic operations tied to regenerative medicine. That blend of R&D and service revenue has made the company more diversified than a pure development-stage biotech, but also exposed it to operational complexity. From a competitive standpoint, U.S. Stem Cell operates in a niche but crowded field. It competes with better-capitalized biotech companies, specialty regenerative-medicine providers, and clinic-based service operators. Its differentiation has historically come from its proprietary therapy concepts, clinical know-how, and physician-facing ecosystem. For investors in France, Belgium, and Switzerland, this is important: the company is not a mainstream large pharmaceutical group, but rather a speculative healthcare micro-cap whose valuation is usually driven by regulatory progress, clinical execution, access to capital, and the ability to convert intellectual property into commercial adoption. Geographically, the business has been primarily U.S.-based, with Florida as its main operational hub, while some training and commercialization efforts have been positioned for broader international reach. Recent public material continues to describe the company as focused on regenerative medicine and cellular therapeutics; however, as with many small biotech names, investors should assume elevated uncertainty around timing, funding, and commercialization. On the U.S. equity market, U.S. Stem Cell remains a name to monitor closely for corporate developments, including SEC Form 4 insider transaction activity and any changes in its reporting or exchange status.